An Injectable Magnesium-Based Cement Stimulated with NIR for Drug-Controlled Release and Osteogenic Potential
© 2024 Wiley‐VCH GmbH..
Magnesium phosphate bone cement (MPC) has gained widespread usage in orthopedic implantation due to its fast-setting and high initial strength benefits. However, the simultaneous attainment of drug-controlled release and osteogenic potential in MPC remains a significant challenge. Herein, a strategy to create a smart injectable cement system using nanocontainers and chondroitin sulfate is proposed. It employs nanocontainers containing alendronate-loaded mesoporous silica nanoparticles, which are surface-modified with polypyrrole to control drug release in response to near-infrared (NIR) stimulation. The alendronate-incorporated cement (ACMPC) exhibits improved compressive strength (70.6 ± 5.9 MPa), prolonged setting time (913 s), and exceptional injectability (96.5% of injection rate and 242 s of injection time). It also shows the capability to prevent degradation, thus preserving mechanical properties. Under NIR irradiation, the cement shows good antibacterial properties due to the combined impact of hyperthermia, reactive oxygen species, and alendronate. Furthermore, the ACMPC (NIR) group displays good biocompatibility and osteogenesis capabilities, which also lead to an increase in alkaline phosphatase activity, extracellular matrix mineralization, and the upregulation of osteogenic genes. This research has significant implications for developing multifunctional biomaterials and clinical applications.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Advanced healthcare materials - (2024) vom: 26. März, Seite e2400207 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhao, Yanbin [VerfasserIn] |
---|
Links: |
---|
Themen: |
Cytocompatibility |
---|
Anmerkungen: |
Date Revised 02.04.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1002/adhm.202400207 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370193989 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370193989 | ||
003 | DE-627 | ||
005 | 20240403000630.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240327s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/adhm.202400207 |2 doi | |
028 | 5 | 2 | |a pubmed24n1361.xml |
035 | |a (DE-627)NLM370193989 | ||
035 | |a (NLM)38529833 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhao, Yanbin |e verfasserin |4 aut | |
245 | 1 | 3 | |a An Injectable Magnesium-Based Cement Stimulated with NIR for Drug-Controlled Release and Osteogenic Potential |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 02.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a © 2024 Wiley‐VCH GmbH. | ||
520 | |a Magnesium phosphate bone cement (MPC) has gained widespread usage in orthopedic implantation due to its fast-setting and high initial strength benefits. However, the simultaneous attainment of drug-controlled release and osteogenic potential in MPC remains a significant challenge. Herein, a strategy to create a smart injectable cement system using nanocontainers and chondroitin sulfate is proposed. It employs nanocontainers containing alendronate-loaded mesoporous silica nanoparticles, which are surface-modified with polypyrrole to control drug release in response to near-infrared (NIR) stimulation. The alendronate-incorporated cement (ACMPC) exhibits improved compressive strength (70.6 ± 5.9 MPa), prolonged setting time (913 s), and exceptional injectability (96.5% of injection rate and 242 s of injection time). It also shows the capability to prevent degradation, thus preserving mechanical properties. Under NIR irradiation, the cement shows good antibacterial properties due to the combined impact of hyperthermia, reactive oxygen species, and alendronate. Furthermore, the ACMPC (NIR) group displays good biocompatibility and osteogenesis capabilities, which also lead to an increase in alkaline phosphatase activity, extracellular matrix mineralization, and the upregulation of osteogenic genes. This research has significant implications for developing multifunctional biomaterials and clinical applications | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a cytocompatibility | |
650 | 4 | |a drug release | |
650 | 4 | |a magnesium phosphate cement | |
650 | 4 | |a nanocontainer | |
650 | 4 | |a photothermal effect | |
700 | 1 | |a Li, Yangyang |e verfasserin |4 aut | |
700 | 1 | |a Wang, Bin |e verfasserin |4 aut | |
700 | 1 | |a Yao, Junyan |e verfasserin |4 aut | |
700 | 1 | |a Fan, Yue |e verfasserin |4 aut | |
700 | 1 | |a He, Peng |e verfasserin |4 aut | |
700 | 1 | |a Bai, Jing |e verfasserin |4 aut | |
700 | 1 | |a Wang, Cheng |e verfasserin |4 aut | |
700 | 1 | |a Xue, Feng |e verfasserin |4 aut | |
700 | 1 | |a Chu, Chenglin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Advanced healthcare materials |d 2012 |g (2024) vom: 26. März, Seite e2400207 |w (DE-627)NLM218710070 |x 2192-2659 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:26 |g month:03 |g pages:e2400207 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/adhm.202400207 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 26 |c 03 |h e2400207 |